Kiniksa Pharmaceuticals (KNSA)

• Market cap: $4.13B
• 1 day: -0.04%
• 5 days: 25.99%
• 1 month: 11.7%
• 3 months: 20.35%
• 6 months: 43.47%
• Year to date: 27.97%
• 1 year: 93.8%
• 5 years: 225.42%
• 10 years: 176.12%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Employees: 366